Document -
Isofol announces successful meetings with European and US regulatory authorities regarding the design of a pivotal Phase II clinical trial of Isofol’s lead Drug candidate, Modufolin®
Isofol Medical AB, will initiate preparations for a pivotal Phase II/III clinical trial in colorectal cancer and, with this trial, has the possibility to complete the clinical development program with only one pivotal efficacy study in each of the two indications being focused on by Isofol (colorectal cancer and osteosarcoma).
-
License:
© All rights reserved
The Content may only be used by Mynewsdesk. It is thus not permissible for anyone else to download, copy, distribute or otherwise use the Content (other than for private use to the extent permitted by law).
- File format: .pdf
